Cite
MLA Citation
Paul M. Barr et al.. “Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.” Leukemia & lymphoma, vol. 63, no. 7, 2022, pp. 1728–1732. http://access.bl.uk/ark:/81055/vdc_100159167102.0x000029